Rituximab for Immune Hemolytic Anemia following T- and B-Cell-Depleted Hematopoietic Stem Cell Transplantation

Authors:
  • SBS. Bonanomi
    S. Bonanomi
  • CVC. Vallinoto
    C. Vallinoto
  • CUC. Uderzo
    C. Uderzo
  • GCG. Cazzaniga
    G. Cazzaniga
  • GGG. Gaipa
    G. Gaipa
  • MDM. Dassi
    M. Dassi
  • PPP. Perseghin
    P. Perseghin
  • ARA. Rovelli
    A. Rovelli

Abstract
The treatment of immune-mediated hemolytic anemia (IHA) complicating hematopoietic stem cell transplantation (HSCT) is often unsatisfactory. We report a case of IHA which occurred after T- and B-cell depleted unrelated donor HSCT carried out for mucopolysaccharidosis type I-H (Hurler syndrome) which was successfully treated with anti-CD20+ monoclonal antibody